Barry Eisenstein received his MD from Columbia University followed by training in Internal Medicine and Infectious Diseases at the University of North Carolina. He has spent his career in academia and industry, serving as chief of the ID division at the University of Texas Health Sciences Center, San Antonio then as Professor and Chair of the Department of Microbiology and Immunology at the University of Michigan. Following four years as VP, Lilly Research Labs, in charge of ID discovery and clinical development, he moved to Boston as VP of Science and Technology, Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School. Since 2003 he has worked at Cubist Pharmaceuticals, where he helped lead the approval process for Cubicin at the FDA and through the Merck acquisition in early 2015 was Senior Vice President, Scientific Affairs. At the end of 2016, he retired from Merck as Distinguished Physician, Antimicrobials, and is now working part-time at CARB-X, a public-private partnership housed at Boston University devoted to new antimicrobial drug and diagnostic development. He is the author of more than 100 original papers, book chapters, and editorials, has edited several books on infectious diseases and microbiology. He was a past editor of both Infection and Immunity (1989-96) and Antimicrobial Agents and Chemotherapy (2004-14). In 2008 he provided testimony before the US Senate on, “Emergence of the Superbug: Antimicrobial Resistance in the U.S.”, and in both 2010 and 2012 before the US Congress hearings on antibiotic resistance that led to the passage of the GAIN Act. He co-chaired a 2010 FDA Workshop panel on endpoints and non-inferiority margins for antibiotic development, and was a panelist at a 2011 joint Pew/IDSA/PhRMA workshop on antibiotic resistance. He was recently a member of the Research Committee and of the Research on Resistance Working Group of the IDSA and chaired the PhRMA taskforce on “emerging pathogens”, a group that met twice in 2012 with FDA leadership to discuss ways to reduce ATB registration hurdles. He was also recently a member of the FNIH Biomarkers Consortium on endpoints in bacterial infections, of the CTTI group working on expediting clinical trials for bacterial infection, of the Brookings Institution Council on Antibacterial Drug Development, and of the IMI DRIVE-AB work project in the EU.